Merck & Co. Inc.'s anti-PD-1 Keytruda has strong potential in combination with paclitaxel chemotherapy in very early treatment of HER2-negative breast cancer, according to new data, but risks are also emerging in this setting and could have implications for other drugs in the class.
Keytruda (pembrolizumab) is currently approved for lung cancer, melanoma, classical Hodgkin lymphoma, head and neck squamous cell cancer, bladder
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?